Profitability Ratios
| Ratio |
Value |
| GP Margin |
51.0% |
| EBIT Margin |
13.1% |
| EBITDA Margin |
23.5% |
| Operating Margin |
9.2% |
| Pretax Margin |
10.8% |
| Cont. Ops Margin |
8.9% |
| Net Margin |
8.9% |
| Bottom Line Margin |
8.0% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
2.71 |
| Quick Ratio |
2.19 |
| Solvency Ratio |
0.189 |
| Cash Ratio |
1.03 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.05 |
| Forward PEG |
-0.05 |
| Price/Book |
2.93 |
| Price/Sales |
1.79 |
| Price/FCF |
9.24 |
| Price/Op Cash Flow |
8.55 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.2258 |
| Debt/Equity |
0.6014 |
| Debt/Capital |
0.3755 |
| Long-Term Debt/Capital |
0.3628 |
| Financial Leverage |
2.66 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
2.18 |
| Operating Cash Flow Ratio |
0.666 |
| Operating Cash Flow/Sales |
21.0% |
| Free Cash Flow/Operating Cash Flow |
92.5% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
5.09 |
| Interest Coverage |
4.0494 |
| Short-Term Operating Cash Flow Coverage |
10.73 |
| Operating Cash Flow Coverage |
0.57 |
| Capital Expenditure Coverage |
13.39 |
| Dividend + Capital Expenditure Coverage |
12.35 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
1.4770% |
| Dividend Yield |
0.0731% |
| Dividend Yield % |
0.0731% |
| Dividend Per Share |
0.0577 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
44.05 |
| EPS |
3.906 |
| Debt/Share |
17.2171 |
| Cash/Share |
14.24 |
| Book Value/Share |
26.96 |
| Tangible BV/Share |
-0.06 |
| Equity/Share |
26.96 |
| Operating Cash Flow/Share |
9.237 |
| Capital Expenditure/Share |
0.690 |
| FCF/Share |
8.547 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.818 |
| Earnings Before Tax/EBIT |
1.179 |
| Price/Fair Value |
2.93 |
| Debt/Market Cap |
0.2054 |
| Effective Tax Rate |
18.2% |
| Enterprise Value Multiple |
7.83 |
ANIP - ANI Pharmaceuticals, Inc.